p-value: p=<0.05
The PPARα agonist fenofibrate suppresses angiogenesis in human umbilical vein endothelial cells in vitro.
BACKGROUND: There are controversial reports about the antiangiogenic effects of peroxisome proliferator-activated receptor α (PPARα). In the current study, we compared the effects of PPARα agonist and antagonist on human umbilical vein endothelial cells (HUVECs) angiogenesis with matrigel assay. MATERIALS AND METHODS: HUVECs (1 × 10(5) cells/well) treated with PPARα agonist (fenofibrate) and antagonist (GW6471) were cultured on matrigel for 24 h. Treated cells were stained with calcein and investigated by fluorescent microscopy. The obtained images were also analyzed by AngioQuant software. Finally, the data were analyzed using SPSS 15 software, Kruskal-Wallis and one way ANOVA. RESULTS: Statistical analysis showed that fenofibrate significantly inhibit the tube formation (size, length, junction) (P < 0.05) but there was a trend to increased angiogenesis in GW6471 treated group (P > 0.05). CONCLUSION: These results showed that PPARα agonist is effective in suppression of angiogenesis. Further studies are needed to confirm these results in in vivo studies.
No takes yet. Share an insight, caveat, or question.
Javanmard et al. (2013) studied Angiogenesis. Fenofibrate (PPARα agonist) vs. DMSO 10% (negative control) was evaluated on Tube formation (size, length, junction) (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: